Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Dec;6(6):789-792.
doi: 10.3748/wjg.v6.i6.789.

Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia

Pankaj Singh, Anant Indaram, Ronald Greenberg, Vernu Visvalingam, Simmy Bank

Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia

Pankaj Singh et al. World J Gastroenterol. 2000 Dec.

Abstract

AIM:To evaluate the long-term safety of omeprazole in patients of gastroesophageal reflux disease resistant to treatment with H2 receptor antagonist.METHODS:We prospectively followed 33 patients on omeprazole therapy for severe erosive esophagitis for 5-8 years, with periodic gastrin levels, H. pyloriinfection, gastric biopsies for incidence of ECL cell hyperplasia, carcinoids, gastric atrophy and neoplasia. A total 185 patient follow-up years and 137 gastric biopsies were done.RESULTS:Among the 33 patients, 36% reached their peak gastrin levels in an average of 8 months to one year, then drifted Down slowly over 1-2 year period to just above their baseline level, 24% of the patients had a peak gastrin level above 400ng·L(-1) and one patient had a peak level above 1000ng·L(-1). One patient had a mild ECL cell hyperplasia which was self limiting and did not show any dysplastic changes. Eighteen percent of patients were positive for H. pylori infection. The gastric biopsies did not show gastric atrophy, intestinal metaplasia or neoplastic changes.CONCLUSION:In a series of 33 patients followed for 5-8 years on omeprazole therapy for severe reflux esophagitis, we did not observe any evidence of significant ECL cell hyperplasia, gastric atrophy, intestinal metaplasia, dysplasia or neoplastic changes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age distribution of patients on long-term omeprazole treatment for reflux esophagitis.
Figure 2
Figure 2
Distribution of follow-up years of patients on long-term omeprazole treatment for reflux esophagitis.
Figure 3
Figure 3
Time to reach maximium plasma gastrin levels in patients treated with long term omeprazole.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shamburek RD, Schubert ML. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K (+)-ATPase inhibitors. Gastroenterol Clin North Am. 1992;21:527–550. - PubMed
    1. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors. Aliment Pharmacol Ther. 1993;7 Suppl 1:13–24, discussion 29-31. - PubMed
    1. Bank S, Blumstein M, Greenberg R, Schulman N, Magier D, Brigante L. Long-term maintenance omeprazole dosing regimens in relation to esophagitis grading in H2RA resistant esophagitis 2-6 years of continuous therapy. Gastroenterology. 1995;108:AS2.
    1. Bank S, Blumstein M, Greenberg R, Austin-Brigante L. Is intermittent or spaced omeprazole dosing in the maintenancetreatment of erosive esophagitis a therapeutic option Results after 2-9 years of continuous therapy. Am J Gastroenterol. 1996;91:1882.
    1. Bank S. Daily or intermittent omeprazole requirements in the long term treatment of erosive esophagitis: results after 2-8 years of continuous therapy. Gastroenterology. 1997;112:A64.